FILE:LH/LH-8K-20050901163140.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 1, 2005 ------------------- (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS ------------------------------------------ (Exact name of registrant as specified in its charter) DELAWARE 1-11353 13-3757370 -------------- ----------- -------------- (State or Other (Commission (IRS Employer Jurisdiction of File Number) Identification Incorporation) Number) 358 SOUTH MAIN STREET BURLINGTON, NORTH CAROLINA 27215 --------------------------------------- ------- (Address of principal executive offices) (Zip Code) 336-229-1127 ------------ (Registrant's telephone number, including area code) N/A --------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ITEM 7.01. Regulation FD Disclosure On September 1, 2005 - Laboratory Corporation of America(R) Holdings (LabCorp(R)) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the Thomas Weisel Partners Healthcare Conference in Boston, MA. LabCorp's presentation is planned for Wednesday, September 7, 2005 at 3:50 p.m. Eastern Time. The press release dated September 1, 2005 is attached herewith as Exhibit 99.1. ITEM 9.01 Financial Statements and Exhibits (c) Exhibits Exhibit Description --------- --------------------------------------------- 99.1 Press Release SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LABORATORY CORPORATION OF AMERICA HOLDINGS ------------------------------------------ (Registrant) By:/s/ BRADFORD T. SMITH -------------------------------------- Bradford T. Smith Executive Vice President and Secretary Date: September 1, 2005 EXHIBIT INDEX Exhibit Description --------- --------------------------------------------- 99.1 Press Release

EXHIBIT 99.1 Laboratory Corporation of America(R) Holdings 358 South Main Street Burlington, NC 27215 Telephone: 336-584-5171 Contact: Scott Fleming - 336-436-4879 Shareholder Direct: (800) LAB-0401 Company Information: www.LabCorp.com LABCORP TO PRESENT AT THE THOMAS WEISEL PARTNERS HEALTHCARE CONFERENCE Burlington, NC, September 1, 2005 - Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the Thomas Weisel Partners Healthcare Conference in Boston, MA. LabCorp's presentation is planned for Wednesday, September 7, 2005 at 3:50 p.m. (ET). A live audio webcast of the presentation will be available via the Company web site at www.labcorp.com. An archived replay of the audio webcast will be available through October 6, 2005. About LabCorp Laboratory Corporation of America(R) Holdings, an S&P 500 company with a BBB investment-grade credit rating, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $3.1 billion in 2004, approximately 25,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; DIANON Systems, Inc. based in Stratford, CT, US LABS based in Irvine, CA, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our growing organization, visit our web site at: www.LabCorp.com. Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2004 and subsequent SEC filings.


